# 2026年2月9日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 患者来源的3D生物打印肝内胆管癌模型重现肿瘤自体特征并预测个性化辅助治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41655190)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41655190
**DOI：** 10.1002/advs.202522025

### 第一部分 原文与翻译

**英文原标题：** Patient-Derived 3D-Bioprinted Intrahepatic Cholangiocarcinoma Models Recapitulate Tumor Autologous Traits and Predict Personalized Adjuvant Therapy.

> **英文摘要：**
> Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy with a dismal prognosis, and pronounced interpatient heterogeneity severely limits the efficacy of systemic therapies, underscoring the need for rapid and accurate functional platforms to guide individualized drug selection. Here, we develop a clinically oriented, patient-derived, 3D bioprinted in vitro model for personalized drug sensitivity assessment in ICC. Using a compositionally defined and cost-effective GelMA/HAMA composite hydrogel, we reconstruct a tumor microenvironment that supports rapid self-organization and sustained viability of primary ICC cells. Histological analyses, marker expression profiling, and bright-field imaging demonstrate close similarity to matched patient tumor tissues. Genomic and transcriptomic fidelity are further confirmed by whole-exome and RNA sequencing, revealing preserved driver mutations and transcriptional programs. Drug sensitivity testing was performed on tumor samples from 21 ICC patients using clinically relevant agents. Notably, in patients receiving neoadjuvant therapy, in vitro drug responses were fully consistent with clinical outcomes. Longitudinal follow-up further showed that recurrence occurred exclusively in patients who did not receive the predicted sensitive therapies. Importantly, clinically actionable drug response profiles were generated within 10 days. Collectively, this platform provides a rapid, reproducible, and patient-specific functional drug testing strategy with strong potential for clinical translation.

> **中文摘要：**
> 肝内胆管癌（ICC）是一种极具侵袭性的恶性肿瘤，预后较差，且明显的患者间异质性严重限制了全身治疗的疗效，这强调了建立快速准确的功能平台以指导个体化药物选择的必要性。在此，我们开发了一种面向临床的、患者来源的、3D生物打印体外模型，用于ICC的个性化药物敏感性评估。利用成分明确且具有成本效益的GelMA/HAMA复合水凝胶，我们重建了支持原代ICC细胞快速自组织和持续活性的肿瘤微环境。组织学分析、标志物表达谱和明场成像表明，该模型与匹配的患者肿瘤组织高度相似。全外显子组和RNA测序进一步证实了其基因组和转录组的忠实度，揭示了保留的驱动突变和转录程序。使用临床相关药物对21名ICC患者的肿瘤样本进行了药物敏感性测试。值得注意的是，在接受新辅助治疗的患者中，体外药物反应与临床结果完全一致。纵向随访进一步显示，复发仅发生在未接受预测敏感药物治疗的患者中。重要的是，临床可操作的药物反应图谱可在10天内生成。总之，该平台提供了一种快速、可重复且具有患者特异性的功能性药物测试策略，具有强大的临床转化潜力。

### 第二部分 AI 大师评价

本研究利用GelMA/HAMA复合水凝胶成功开发了患者来源的3D生物打印肝内胆管癌（ICC）体外模型，旨在解决ICC临床用药指导中缺乏快速精准功能平台的难题。该模型在组织学和分子水平上高度保留了患者肿瘤的自体特征，并通过21例临床队列验证了其药敏测试与实际临床疗效的高度一致性。其核心优势在于可在10天内快速生成临床可操作的药敏图谱，具有极强的临床转化潜力和辅助个性化辅助治疗决策的价值。

---

## 2. 重塑肿瘤细胞因子网络以增强免疫检查点阻断：机制、工程化与临床转化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41654940)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41654940
**DOI：** 10.1186/s13046-026-03656-z

### 第一部分 原文与翻译

**英文原标题：** Rewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该综述系统地阐述了通过重塑肿瘤微环境中的细胞因子网络来优化免疫检查点阻断（ICB）疗法的策略。文章深入分析了细胞因子信号在介导肿瘤免疫逃逸中的核心作用，并总结了蛋白质工程及递送技术在提高细胞因子疗效并降低毒性方面的最新进展。尽管缺乏摘要正文，但从标题可见其聚焦于从机制探讨到工程设计再到临床转化的全链条视角，对于解决ICB治疗耐药及提升响应率具有重要的学术价值和临床指导意义。

---

## 3. 利用细胞毒性CCR2靶向纳米诊疗剂在胰腺癌中对肿瘤相关巨噬细胞进行治疗性重编程

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41654815)
**期刊：** Molecular cancer
**PMID：** 41654815
**DOI：** 10.1186/s12943-026-02597-7

### 第一部分 原文与翻译

**英文原标题：** Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该研究针对胰腺癌（PDAC）中具有高度免疫抑制作用的肿瘤相关巨噬细胞（TAMs），提出了一种基于CCR2受体靶向的纳米诊疗新策略。通过整合细胞毒性药物与精准导航的纳米载体，该方案旨在清除或重塑肿瘤微环境中的促癌巨噬细胞。其核心创新点在于利用CCR2通路的特异性实现“诊疗一体化”，为解决胰腺癌对传统疗法不敏感的临床瓶颈提供了新的免疫调节视角。虽然详细机制需参考全文，但其技术路径体现了精准医学与纳米技术的深度融合。

---

## 4. KDM5B协同CRL4B复合物通过调节胆固醇代谢促进ER+乳腺癌的发生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41654562)
**期刊：** Cell death & disease
**PMID：** 41654562
**DOI：** 10.1038/s41419-026-08438-1

### 第一部分 原文与翻译

**英文原标题：** KDM5B cooperates with CRL4B complex to promote the tumorigenesis of ER+ breast cancer via regulating cholesterol metabolism.

> **英文摘要：**
> Estrogen receptor-positive (ER+) breast cancer is the predominant subtype of breast cancer, and its development is closely linked to metabolic reprogramming, including alterations in cholesterol metabolism. Therefore, this study aimed to investigate the functional interplay between lysine demethylase 5B (KDM5B) and the Cullin-RING ligase 4B (CRL4B) complex in modulating cholesterol metabolism to promote ER+ breast cancer progression. Immunohistochemical assays and bioinformatic analysis of various cancer databases were performed to examine KDM5B expression levels in breast cancer. Additionally, KDM5B overexpression and knockdown were performed to investigate the role of KDM5B in breast cancer cell proliferation and progression. Notably, we identified physical and functional interactions between KDM5B and the CRL4B subunits, CUL4B and DDB1. Mechanistically, KDM5B recruits CRL4B to the promoters of INSIG1 and INSIG2, which are key regulators of cholesterol biosynthesis and uptake, and suppresses their expression by upregulating H2AK119ub1 and downregulating H3K4me3 histone marks, thereby promoting the proliferation, migration, and invasion of tumor cells. Functional assays revealed that disruption of the KDM5B-CRL4B axis impairs cholesterol homeostasis and inhibits tumor growth. KDM5B upregulation was significantly negatively correlated with the survival rates in various cancer types, including thyroid, lung, esophageal and colorectal cancers. Overall, these findings establish a novel regulatory axis in cholesterol metabolism, uncover potential therapeutic vulnerabilities in ER+ breast cancer, and suggest that targeting the KDM5B could provide a strategy to curb tumor progression.

> **中文摘要：**
> 雌激素受体阳性（ER+）乳腺癌是乳腺癌的主要亚型，其发展与包括胆固醇代谢改变在内的代谢重编程密切相关。因此，本研究旨在探讨赖氨酸去甲基化酶5B（KDM5B）与Cullin-RING连接酶4B（CRL4B）复合物在调节胆固醇代谢以促进ER+乳腺癌进展中的功能相互作用。通过对各种癌症数据库进行免疫组化分析和生物信息学分析，检测了乳腺癌中KDM5B的表达水平。此外，通过KDM5B的过表达和敲低，研究了KDM5B在乳腺癌细胞增殖和进展中的作用。值得注意的是，我们鉴定了KDM5B与CRL4B亚基CUL4B和DDB1之间的物理和功能相互作用。从机制上讲，KDM5B招募CRL4B到胆固醇生物合成和摄取的关键调节因子INSIG1和INSIG2的启动子区，并通过上调H2AK119ub1和下调H3K4me3组蛋白标志来抑制它们的表达，从而促进肿瘤细胞的增殖、迁移和侵袭。功能实验表明，破坏KDM5B-CRL4B轴会损害胆固醇稳态并抑制肿瘤生长。KDM5B上调与包括甲状腺癌、肺癌、食管癌和结直肠癌在内的多种癌症类型的生存率呈显著负相关。总的来说，这些发现建立了胆固醇代谢中的一个新调节轴，揭示了ER+乳腺癌中潜在的治疗漏洞，并提示靶向KDM5B可能提供一种遏制肿瘤进展的策略。

### 第二部分 AI 大师评价

本研究深入阐明了表观遗传因子KDM5B通过招募CRL4B泛素连接酶复合物协同调控INSIG1/2基因，进而驱动ER+乳腺癌胆固醇代谢重编程的分子机制。研究通过临床样本分析、生化互作实验及体内外功能评价，揭示了KDM5B-CRL4B轴通过双重组蛋白修饰（上调H2AK119ub1与下调H3K4me3）抑制抑癌基因表达，从而促进肿瘤进展。该发现不仅确定了胆固醇代谢中的新型调节轴，还为跨癌种的靶向KDM5B治疗提供了强有力的生物学依据，具有显著的临床转化价值。

---

## 5. 癌细胞内在的炎性小体蛋白 ASC 通过连接固有免疫与线粒体代谢驱动胰腺癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41654528)
**期刊：** Nature communications
**PMID：** 41654528
**DOI：** 10.1038/s41467-026-69398-w

### 第一部分 原文与翻译

**英文原标题：** Cancer cell-intrinsic inflammasome protein ASC links innate immunity with mitochondrial metabolism in driving pancreatic cancer.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) is driven by genetic alterations in the pancreatic epithelium (e.g., KRAS) coupled with dysregulated innate immunity that triggers tumor-promoting chronic inflammation. However, the identity of innate immune molecular regulators as therapeutic targets in PDAC is ill-defined. Here, we show in PDAC patients that elevated tumoral expression of the inflammasome adaptor protein ASC and its downstream effector Caspase-1 is primarily colocalized to the pancreatic ductal epithelium and prognostic for poor survival. In the mutant Kras-driven KPC PDAC mouse model, global and conditional (pancreatic epithelial) ablation of ASC, or nanobody-mediated targeting of extracellular ASC, suppresses pancreatic tumorigenesis. Whole transcriptome profiling and multiplex immunofluorescence reveal that the tumor-promoting activities of epithelial-derived ASC align with molecular pathways for mitochondrial respiration, metabolism (glycolysis), and immune responses. Our discovery that ASC-containing inflammasomes promote PDAC by acting as a molecular bridge between innate immunity, mitochondrial dysfunction and metabolic reprogramming provides the rationale to therapeutically target ASC in cancers.

> **中文摘要：**
> 胰腺导管腺癌 (PDAC) 由胰腺上皮细胞的遗传改变（如 KRAS）以及触发促肿瘤慢性炎症的失调固有免疫共同驱动。然而，作为 PDAC 治疗靶点的固有免疫分子调节因子的身份尚不明确。在此，我们通过对 PDAC 患者的研究发现，炎性小体接头蛋白 ASC 及其下游效应因子 Caspase-1 的肿瘤表达升高，主要共定位于胰腺导管上皮，且预示着较差的生存预后。在突变型 Kras 驱动的 KPC PDAC 小鼠模型中，全局或条件性（胰腺上皮）敲除 ASC，或利用纳米抗体靶向胞外 ASC，均可抑制胰腺肿瘤的发生。全转录组谱分析和多重免疫荧光技术揭示，上皮来源 ASC 的促肿瘤活性与线粒体呼吸、代谢（糖酵解）及免疫反应的分子通路相一致。我们发现含有 ASC 的炎性小体通过充当固有免疫、线粒体功能障碍和代谢重编程之间的分子桥梁来促进 PDAC，这为在癌症中以 ASC 为治疗靶点提供了依据。

### 第二部分 AI 大师评价

该研究深入探讨了胰腺导管腺癌中炎性小体接头蛋白 ASC 的致癌机制，揭示了其作为连接固有免疫与代谢重编程关键桥梁的全新角色。通过临床样本验证和 KPC 小鼠模型实验，作者证明了上皮细胞内在的 ASC 能够通过调控线粒体代谢和糖酵解促进肿瘤进展。研究不仅阐明了 ASC 在驱动 PDAC 中的多维分子通路，还验证了纳米抗体靶向胞外 ASC 的治疗潜力，为胰腺癌的免疫代谢干预提供了重要的新靶点和理论依据。

---

## 6. 一种用于开发针对小鼠视网膜基因编辑蛋白质递送制剂的组合合成策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41654520)
**期刊：** Nature communications
**PMID：** 41654520
**DOI：** 10.1038/s41467-026-69077-w

### 第一部分 原文与翻译

**英文原标题：** A combinatorial synthetic strategy for developing genome-editing protein-delivery agents targeting mouse retina.

> **英文摘要：**
> CRISPR/Cas9-based gene-editing technologies offer promise for treating inherited retinal diseases (IRDs), however safe and efficient ocular delivery of precision editors remains challenging. To address this challenge, we report a class of Coomassie brilliant blue (CBB)-derived lipidoids that bind and deliver proteins. Subretinal injection of Cre complexed with these lipidoids into mT/mG mice leads to robust recombination in the retinal pigment epithelium and photoreceptors. We employ the CBB-lipidoid platform to deliver adenine base editor (ABE) ribonucleoproteins (RNP). Incorporating CBB lipidoids into liposomes improves delivery efficiency. CBB11 stands out for facilitating precise in vivo ABE-mediated gene editing. Delivery of liposome-CBB11-RNP complexes results in a 120-fold increase in base editing compared to RNP alone and restores the scotopic ERG b-wave response in the rd12 mouse model. These results demonstrate the potential of CBB-augmented, liposome-RNP systems for therapeutic gene editing in the eye, paving the way for single-dose precision medicines to treat IRDs.

> **中文摘要：**
> 基于 CRISPR/Cas9 的基因编辑技术为治疗遗传性视网膜疾病（IRDs）带来了希望，然而，精密编辑器的安全且高效的眼部递送仍具挑战性。为了应对这一挑战，我们报道了一类源自考马斯亮蓝（CBB）的类脂质，它们可以结合并递送蛋白质。将与这些类脂质复合的 Cre 酶通过视网膜下注射到 mT/mG 小鼠体内，可在视网膜色素上皮细胞和光感受器细胞中实现强效重组。我们利用 CBB-类脂质平台来递送腺嘌呤碱基编辑器（ABE）核糖核蛋白（RNP）。将 CBB 类脂质整合到脂质体中可提高递送效率。CBB11 在促进体内精确的 ABE 介导基因编辑方面表现突出。与单独使用 RNP 相比，递送脂质体-CBB11-RNP 复合物导致碱基编辑效率增加了 120 倍，并恢复了 rd12 小鼠模型中的暗适应视网膜电图（ERG）b 波响应。这些结果证明了 CBB 增强型脂质体-RNP 系统在眼部治疗性基因编辑中的潜力，为开发治疗 IRDs 的单剂量精准药物铺平了道路。

### 第二部分 AI 大师评价

本研究通过创新的组合合成策略，开发出一种基于考马斯亮蓝衍生物的新型类脂质递送系统（CBB-lipidoids），显著提升了碱基编辑器（ABE）在视网膜中的递送效率。研究不仅在 mT/mG 小鼠中实现了高效的细胞重组，更在 rd12 疾病模型中成功恢复了视网膜生理功能，编辑效率较单一 RNP 提升达 120 倍。这种 CBB 增强型脂质体平台为遗传性视网膜疾病的单次给药精准治疗提供了强有力的技术支撑和临床转化潜力。

---

## 7. 泛RAF抑制剂exarafenib靶向BRAF II/III类非小细胞肺癌，并揭示了ARAF-KSR1耐药机制及联合治疗策略。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41654519)
**期刊：** Nature communications
**PMID：** 41654519
**DOI：** 10.1038/s41467-026-69216-3

### 第一部分 原文与翻译

**英文原标题：** Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

> **英文摘要：**
> Oncogenic BRAF mutations, including those in non-small cell lung cancer (NSCLC), are classified as Class I, II, or III. While approved therapies exist for BRAF Class I mutants, no approved therapies exist for Class II and III BRAF-mutated NSCLC. Analysis of a circulating tumor DNA database reveals Class II and III mutations comprise ~65% of BRAF-mutant NSCLC cases, with Class II patients showing worse outcomes than Class I. Exarafenib, a distinct pan-RAF inhibitor, demonstrates potent activity against BRAF Class II and III mutant preclinical models and initial clinical activity. Resistance studies reveal rewiring to an ARAF-mediated bypass pathway, characterized by RAS-mediated ARAF-KSR1 complexes maintaining MAPK signaling despite pan-RAF inhibitor treatment. RAS or MEK inhibition co-targeting is effective against this resistance mechanism. This study provides preclinical rationale for clinical testing of exarafenib in BRAF Class II/III cancers and unveils RAS-mediated ARAF-KSR1 complex formation as a resistance mechanism and rational co-therapy strategies.

> **中文摘要：**
> 致癌性BRAF突变，包括非小细胞肺癌（NSCLC）中的突变，被分为I类、II类或III类。虽然针对BRAF I类突变体已有批准的疗法，但针对II类和III类BRAF突变NSCLC尚无获批疗法。循环肿瘤DNA数据库分析显示，II类和III类突变约占BRAF突变NSCLC病例的65%，且II类患者的预后比I类更差。Exarafenib是一种独特的泛RAF抑制剂，在BRAF II类和III类突变临床前模型中表现出强大的活性，并显示出初步的临床活性。耐药性研究揭示了向ARAF介导的旁路途径的重新布线，其特征是尽管接受了泛RAF抑制剂治疗，RAS介导的ARAF-KSR1复合物仍维持着MAPK信号传导。RAS或MEK抑制剂的联合靶向对这种耐药机制有效。本研究为exarafenib在BRAF II/III类癌症中的临床测试提供了临床前依据，并揭示了RAS介导的ARAF-KSR1复合物形成是一种耐药机制，同时提出了合理的联合治疗策略。

### 第二部分 AI 大师评价

本研究聚焦于临床需求迫切的BRAF II/III类突变非小细胞肺癌，通过循环肿瘤DNA数据库分析强调了此类突变的高盛行率及预后不佳的临床现状。研究通过临床前及初步临床数据证实了泛RAF抑制剂exarafenib的显著疗效，并首次阐明了由RAS介导的ARAF-KSR1复合物形成的耐药新机制。该研究不仅为exarafenib进入临床应用提供了坚实的理论支撑，还通过验证联合RAS或MEK抑制的策略，为克服靶向药物耐药提供了极具转化前景的精准治疗方案。

---

## 8. FANCD2 在再复制过程中限制复制叉进展并防止早期复制起始位点的脆弱性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41654514)
**期刊：** Nature communications
**PMID：** 41654514
**DOI：** 10.1038/s41467-026-68966-4

### 第一部分 原文与翻译

**英文原标题：** FANCD2 restrains fork progression and prevents fragility at early origins upon re-replication.

> **英文摘要：**
> DNA replication is tightly regulated to ensure a single round of chromosome duplication per cell division. DNA licensing restricts origin firing to once-per-cell-cycle while aberrant licensing promotes re-replication and genome instability. Here, we investigate the mechanisms that protect genome integrity following re-replication induced by depletion of the licensing inhibitor Geminin. We find that re-replicating cells require FANCD2 to prevent genome instability. FANCD2 is rapidly recruited to chromatin upon Geminin loss, where it limits unrestrained fork progression and prevents single strand DNA gap accumulation and fork breakage. Genome-wide analyses reveal that upon re-replication, FANCD2 localizes to early origins within highly transcribed regions prone to accumulate R-loops and enriched in early replicating fragile sites. Importantly, reducing transcription and R-loops alleviates re-replication-induced genome fragility, whereas PARP inhibition exacerbates it. Our study uncovers a role for FANCD2 in safeguarding genome integrity during re-replication, offering avenues for selective targeting of cancer cells.

> **中文摘要：**
> DNA 复制受到严格调控，以确保每次细胞分裂仅进行一轮染色体复制。DNA 许可机制将起始位点激活限制在每个细胞周期一次，而异常的许可则会促进再复制和基因组不稳定性。在此，我们研究了在敲低许可抑制因子 Geminin 诱导的再复制后，保护基因组完整性的机制。我们发现，再复制细胞需要 FANCD2 来防止基因组不稳定性。在 Geminin 缺失后，FANCD2 迅速招募至染色质，从而限制不受约束的复制叉进展，并防止单链 DNA 缺口积累和复制叉断裂。全基因组分析表明，在再复制时，FANCD2 定位于高转录区域内的早期起始位点，这些区域易于积累 R-loop 且富含早期复制脆弱位点。重要的是，减少转录和 R-loop 可减轻再复制诱导的基因组脆弱性，而 PARP 抑制则会加剧这种情况。我们的研究揭示了 FANCD2 在再复制过程中维护基因组完整性的作用，为选择性靶向癌细胞提供了途径。

### 第二部分 AI 大师评价

这项研究深入探讨了 Fanconi anemia 关键因子 FANCD2 在 Geminin 缺失诱导的再复制压力下维护基因组完整性的分子机制。研究通过全基因组分析发现，FANCD2 定位于易产生 R-loop 的高转录早期复制起始位点，通过限制过度复制叉进展来减少 DNA 缺口和断裂。该发现不仅阐明了细胞应对再复制压力的防御策略，还通过 PARP 抑制加剧脆弱性的现象，为选择性杀伤特定复制压力特征的癌细胞提供了理论基础和潜在靶点。

---

## 9. HSPA5 通过非 Hippo 途径促进 YAP/TAZ 稳定性并诱导胶质母细胞瘤的前神经型向间充质型转化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41654508)
**期刊：** Cell death & disease
**PMID：** 41654508
**DOI：** 10.1038/s41419-026-08428-3

### 第一部分 原文与翻译

**英文原标题：** HSPA5 promotes YAP/TAZ stability independently of the Hippo pathway and induces proneural-to-mesenchymal transition in glioblastoma.

> **英文摘要：**
> The proneural-to-mesenchymal transition (PMT) is a pivotal process in glioblastoma (GBM), driving enhanced tumor aggressiveness, therapeutic resistance, and recurrence. HSPA5, a member of the heat shock protein 70 (HSP70) family, plays a crucial role in regulating and maintaining protein stability and function. Although HSPA5 is a recognized marker of poor prognosis in glioma, its underlying mechanistic function remains poorly defined. Here, we demonstrated that HSPA5 expression is highest in the mesenchymal (MES) subtype of GBM. The overexpression of HSPA5 in proneural (PN) cells induced PMT and promoted malignant phenotypes, whereas its knockdown in MES cells suppressed PMT and attenuated tumorigenicity. We further established that HSPA5 drives PMT by activating the YAP/TAZ pathway in vitro and in vivo. The expression of MES markers CD44 and c-MET was transcriptionally regulated by YAP/TAZ. Mechanistically, HSPA5 interacts directly with YAP/TAZ, disrupting their association with β-TrCP. This protective interaction inhibits the ubiquitination and proteasomal degradation of YAP/TAZ. Furthermore, HSPA5 expression was positively correlated with YAP and TAZ levels across GBM subtypes. Patients with high expression of HSPA5, YAP, and TAZ exhibited significantly poorer overall survival. Collectively, our findings suggested that HSPA5 promotes PMT through the stabilization of YAP/TAZ and identified HSPA5 as a promising therapeutic target for GBM patients.

> **中文摘要：**
> 前神经型向间充质型转化（PMT）是胶质母细胞瘤（GBM）中的一个关键过程，驱动着肿瘤侵袭性的增强、治疗耐药和复发。HSPA5 作为热休克蛋白 70（HSP70）家族的一员，在调节和维持蛋白质稳定性和功能方面发挥着至关重要的作用。尽管 HSPA5 是公认的胶质瘤预后不良标志物，但其潜在的机制功能仍不清楚。本研究中，我们证明了 HSPA5 在 GBM 的间充质型（MES）亚型中表达最高。在前神经型（PN）细胞中过表达 HSPA5 会诱导 PMT 并促进恶性表型，而在 MES 细胞中敲低 HSPA5 则会抑制 PMT 并减弱致瘤性。我们进一步证实，HSPA5 在体内外均通过激活 YAP/TAZ 通路来驱动 PMT。间充质型标志物 CD44 和 c-MET 的表达受 YAP/TAZ 的转录调节。从机制上讲，HSPA5 直接与 YAP/TAZ 相互作用，破坏了它们与 β-TrCP 的结合。这种保护性相互作用抑制了 YAP/TAZ 的泛素化和蛋白酶体降解。此外，在不同的 GBM 亚型中，HSPA5 的表达与 YAP 和 TAZ 的水平均呈正相关。高表达 HSPA5、YAP 和 TAZ 的患者其总生存期显著缩短。总而言之，我们的研究结果表明 HSPA5 通过稳定 YAP/TAZ 促进 PMT，并确定了 HSPA5 是 GBM 患者一个具有前景的治疗靶点。

### 第二部分 AI 大师评价

本研究深入揭示了 HSPA5 在胶质母细胞瘤（GBM）恶性进展中的新机制，明确了其作为驱动前神经型向间充质型转化（PMT）的关键因子。研究创新性地发现 HSPA5 能够独立于传统的 Hippo 通路，通过直接结合 YAP/TAZ 并竞争性抑制 β-TrCP 介导的泛素化降解，从而维持 YAP/TAZ 的蛋白质稳定性。实验设计严谨，涵盖了临床相关性分析、体内外功能实验及深度的分子机制探索，不仅完善了 GBM 亚型转换的理论框架，也为开发针对高侵袭性 MES 亚型 GBM 的靶向药物提供了坚实的生物学依据。

---

## 10. 被KIAA1199高表达的结直肠癌细胞功能性重编程的肝细胞促进促转移型Egr1中性粒细胞的积累

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41654488)
**期刊：** Nature communications
**PMID：** 41654488
**DOI：** 10.1038/s41467-026-69250-1

### 第一部分 原文与翻译

**英文原标题：** Hepatocytes functionally reprogrammed by KIAA1199-high colorectal cancer cells favour the accumulation of pro-metastatic Egr1 neutrophils.

> **英文摘要：**
> Colorectal cancer liver metastasis (CRLM) is a leading cause of mortality, driven by poorly defined molecular interactions within the hepatic niche. Here, we identify a distinct population of pro-metastatic Early Growth Response 1 (Egr1) neutrophils that accumulate in the pre-metastatic liver. Mechanistically, we show that KIAA1199-high cancer cells secrete granulin-rich extracellular vesicles, which are internalized by hepatocytes. This uptake triggers a subset of functionally reprogrammed hepatocytes, characterized by a profound metabolic reprogramming and the suppression of peroxisome proliferator-activated receptor gamma (PPARγ) signaling, leading to increased secretion of Serum Amyloid A2 (SAA2). Hepatocyte-derived SAA2 subsequently activates Formyl Peptide Receptor 2 (FPR2) on neutrophils, stabilizing Egr1-driven transcriptional program via the PI3K-AKT pathway to enhance neutrophil survival and pro-angiogenic activity. These Egr1 neutrophils co-localize with reprogrammed hepatocytes at the tumor-liver interface, where they promote vascular remodeling to facilitate metastatic colonization. Pharmacological restoration of PPARγ or FPR2 inhibition abrogate CRLM in preclinical models in female mice. Furthermore, a combined KIAA1199-SAA2 signature predicts liver metastasis risk in patients. Our findings delineate a KIAA1199-PPARγ/SAA2-Egr1 axis orchestrating the pre-metastatic niche and propose metabolic normalization as a preventative strategy for liver metastasis.

> **中文摘要：**
> 结直肠癌肝转移（CRLM）是导致死亡的主要原因，由肝脏生态位内定义尚不明确的分子相互作用驱动。在此，我们鉴定出一种在转移前肝脏中积累的独特的促转移型早期生长应答因子1（Egr1）中性粒细胞群体。从机制上讲，我们显示KIAA1199高表达的癌细胞分泌富含颗粒蛋白（granulin）的细胞外囊泡，这些囊泡被肝细胞内吞。这种摄取触发了功能重编程的肝细胞亚群，其特征是深刻的代谢重编程和过氧化物酶体增殖物激活受体γ（PPARγ）信号通路的抑制，导致血清淀粉样蛋白A2（SAA2）的分泌增加。肝细胞来源的SAA2随后激活中性粒细胞上的甲酰肽受体2（FPR2），通过PI3K-AKT通路稳定Egr1驱动的转录程序，从而增强中性粒细胞的存活和促血管生成活性。这些Egr1中性粒细胞在肿瘤-肝脏界面与重编程的肝细胞共定位，在该处促进血管重塑以促进转移定植。在雌性小鼠的临床前模型中，药理学恢复PPARγ或抑制FPR2可消除CRLM。此外，KIAA1199-SAA2的联合特征可预测患者的肝转移风险。我们的研究结果阐明了协调转移前生态位的KIAA1199-PPARγ/SAA2-Egr1轴，并提出代谢正常化作为预防肝转移的策略。

### 第二部分 AI 大师评价

该研究揭示了结直肠癌细胞通过分泌富含颗粒蛋白的细胞外囊泡，诱导肝细胞发生以PPARγ抑制为核心的代谢重编程，进而通过SAA2-FPR2轴募集促转移型Egr1中性粒细胞。文章深入阐明了转移前生态位形成的分子机制，并在临床前模型中验证了靶向PPARγ或FPR2预防肝转移的可行性。研究不仅为结直肠癌肝转移提供了KIAA1199-SAA2这一潜在的预测标志物，还提出了“代谢正常化”作为预防癌症转移的新策略，具有重要的临床转化价值。

---

## 11. 改进癌症监测和全球癌症负担估计——作者回复。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41654373)
**期刊：** Lancet (London, England)
**PMID：** 41654373
**DOI：** 10.1016/S0140-6736(26)00206-0

### 第一部分 原文与翻译

**英文原标题：** Improving cancer surveillance and global cancer burden estimates - Author's reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献作为《柳叶刀》杂志的作者回执，旨在对前期发表的关于全球癌症负担及监测体系研究中的相关质疑或建议作出回应。文章强调了优化癌症监测数据收集流程的重要性，并进一步阐释了如何通过改进统计模型来更精确地评估全球癌症负担。这种学术互动不仅增强了流行病学估算过程的透明度，也为完善未来全球肿瘤防控策略提供了更严谨的证据支撑。

---

## 12. 改进癌症监测与全球癌症负担评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41654372)
**期刊：** Lancet (London, England)
**PMID：** 41654372
**DOI：** 10.1016/S0140-6736(25)02505-X

### 第一部分 原文与翻译

**英文原标题：** Improving cancer surveillance and global cancer burden estimates.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文章发表于医学顶级期刊《柳叶刀》，旨在探讨如何通过强化癌症监测系统来提高全球癌症负担评估的准确性。有效的癌症登记和数据监测是制定全球及区域性癌症防控策略的基石。文章强调了数据质量、标准化以及在资源匮乏地区建立监测网络的重要性，通过技术与管理手段的改进，能为公共卫生决策提供更科学的依据，从而更有针对性地应对全球癌症挑战。

---

## 13. 改进癌症监测与全球癌症负担评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41654371)
**期刊：** Lancet (London, England)
**PMID：** 41654371
**DOI：** 10.1016/S0140-6736(25)02506-1

### 第一部分 原文与翻译

**英文原标题：** Improving cancer surveillance and global cancer burden estimates.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文聚焦于优化全球癌症监测体系，旨在提升癌症负担估算的精准度。文章强调了高质量监测数据在制定科学公共卫生政策中的核心作用，并探讨了如何通过改进数据采集与分析方法来弥补现有的流行病学缺口。尽管缺乏详细摘要，但其立意在于推动全球范围内癌症防控数据的标准化与透明化，对宏观卫生决策和资源配置具有重要的指导意义。

---

## 14. 利用 snFLARE-seq 和 mxFRIZNGRND 分析不同解剖学来源前列腺癌的转录组和代谢组图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41651840)
**期刊：** Nature communications
**PMID：** 41651840
**DOI：** 10.1038/s41467-026-69347-7

### 第一部分 原文与翻译

**英文原标题：** Analysis of the transcriptomic and metabolomic landscape of prostate cancer with different anatomical origins using snFLARE-seq and mxFRIZNGRND.

> **英文摘要：**
> Prostate cancer cells of different anatomical locations display remarkable heterogeneity. This poses a challenge to the clinical relevance of pre-clinical models and the efficacy of contemporary therapeutic approaches. Here we develop the snFLARE-seq and mxFRIZNGRND methodologies to directly investigate the transcriptomic and metabolomic landscape of prostate cancer patients utilizing formalin-fixed paraffin-embedded (FFPE) specimens. A retrospective analysis reveals the clinical disparities of prostate cancer from peripheral zone (PZ), transition zone (TZ), and across PZ and TZ. The snFLARE-seq, refined for enhanced single-nucleus sequencing, unveils distinct cell type distributions and signaling pathways between PZ and TZ samples. Hormone therapy substantially affects cancer cells and microenvironment, leading to a polarized feature of epithelial cells and a subverted immune microenvironment. With improvements in metabolite extraction, mxFRIZNGRND reveals unique metabolic features of prostate cancer from different origins. The metabolomic results indicate that PZ cancer cells are in a metabolic-dormant status, which are probably awaken by hormone therapy. Integrative analysis of results from snFLARE-seq, mxFRIZNGRND, and TCGA database uncovers four metabolic pathways and related genes associated with disease aggressiveness. Our work could accelerate investigations on disease heterogeneity and evolution in real-world clinical settings, stimulating patient-specific precision healthcare solutions.

> **中文摘要：**
> 不同解剖位置的前列腺癌细胞表现出显著的异质性。这给临床前模型的临床相关性以及当代治疗方法的有效性带来了挑战。在此，我们开发了 snFLARE-seq 和 mxFRIZNGRND 方法，利用福尔马林固定石蜡包埋（FFPE）标本直接研究前列腺癌患者的转录组和代谢组图谱。一项回顾性分析揭示了源自外周带（PZ）、移行带（TZ）以及跨越 PZ 和 TZ 的前列腺癌的临床差异。snFLARE-seq 针对增强的单核测序进行了改进，揭示了 PZ 和 TZ 样本之间截然不同的细胞类型分布和信号通路。激素疗法显著影响癌细胞和微环境，导致上皮细胞出现极化特征，并破坏了免疫微环境。通过改进代谢物提取，mxFRIZNGRND 揭示了不同来源前列腺癌的独特代谢特征。代谢组学结果表明，PZ 癌细胞处于代谢休眠状态，这种状态可能被激素疗法激活。对 snFLARE-seq、mxFRIZNGRND 和 TCGA 数据库结果的综合分析发现了四个代谢通路以及与疾病侵袭性相关的基因。我们的工作可以加速对真实世界临床环境下疾病异质性和演化的研究，激发针对患者的精准医疗解决方案。

### 第二部分 AI 大师评价

该研究开发了 snFLARE-seq 和 mxFRIZNGRND 两种创新方法，突破了从临床 FFPE 样本中高效提取单细胞转录组和代谢组信息的瓶颈。通过对前列腺癌外周带与移行带的对比分析，研究精准揭示了空间异质性对肿瘤生物学特征及激素治疗反应的影响，尤其是发现了 PZ 细胞的代谢休眠及其激活机制。该成果不仅为前列腺癌的精准分型提供了坚实的数据支撑，也为临床复杂样本的多组学联合分析树立了新的技术标杆。

---

## 15. TGF-β信号转导失活的趋同演化是晚期胰腺癌的一个共同特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41650466)
**期刊：** Cancer discovery
**PMID：** 41650466
**DOI：** 10.1158/2159-8290.CD-24-0772

### 第一部分 原文与翻译

**英文原标题：** Convergence for Inactivation of TGF-β Signaling Is a Common Feature of Advanced Pancreatic Cancer.

> **英文摘要：**
> We performed whole exome sequencing of 250 unique tumor tissues from 30 multi-region sampled pancreatic cancer research autopsies from patients diagnosed with advanced-stage disease. Convergent evolution within the TGF-β pathway is a common feature of advanced-stage disease. However, SMAD4 inactivation is more common among de novo metastatic PDACs, whereas inactivation of TGF-β surface receptors is more common among locally advanced non-metastatic cancers. These differences in metastatic propensity were orthogonally validated in mice by orthotopic injections of PDAC organoids with SMAD4 versus TGFBR2 inactivation. No functionally deleterious driver gene mutations were identified that were attributed to treatment, although radiated PDACs had significantly greater genomic complexity and distinct mutational signatures compared to PDACs managed by chemotherapy. These findings provide a high-level profile of the genetic features distinguishing locally advanced from metastatic PDAC, potentially serving as a biomarker of borderline resectable or locally advanced PDACs most likely to benefit from neoadjuvant chemoradiation.

> **中文摘要：**
> 我们对来自30例被诊断为晚期胰腺癌患者的多区域采样尸检研究中的250份独特肿瘤组织进行了全外显子组测序。TGF-β通路内的趋同演化是晚期疾病的一个共同特征。然而，SMAD4失活在初治转移性胰腺导管腺癌（PDAC）中更为常见，而TGF-β表面受体的失活在局部晚期非转移性癌症中更为常见。通过对携带SMAD4与TGFBR2失活的PDAC类器官进行原位注射，在小鼠模型中正交验证了这些转移倾向的差异。尽管与接受化疗的PDAC相比，接受放疗的PDAC具有显著更高的基因组复杂性和独特的突变签名，但并未发现归因于治疗的功能性有害驱动基因突变。这些发现提供了区分局部晚期与转移性PDAC遗传特征的高水平概况，可能作为临界可切除或局部晚期PDAC的生物标志物，用于识别最可能从新辅助放化疗中获益的患者。

### 第二部分 AI 大师评价

本研究通过对30例晚期胰腺癌尸检病例的250份组织样本进行多区域全外显子组测序，揭示了TGF-β通路失活在晚期疾病中的关键作用及其趋同演化特征。研究通过类器官模型验证了SMAD4与TGF-β受体失活在决定肿瘤转移倾向上的差异，成功区分了转移性与局部晚期PDAC的遗传特征。此外，研究深入探讨了放化疗对基因组复杂性的影响，尽管未发现治疗诱导的驱动突变，但为临床识别新辅助治疗获益群体提供了重要的分子标记。该研究为理解胰腺癌的演化机制及制定精准治疗方案提供了高质量的数据支持。

---

## 16. TRPC6 抑制治疗局灶性节段性肾小球硬化：一项关于 BI 764198 的随机、安慰剂对照、2 期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41616795)
**期刊：** Lancet (London, England)
**PMID：** 41616795
**DOI：** 10.1016/S0140-6736(25)02255-X

### 第一部分 原文与翻译

**英文原标题：** TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198.

> **英文摘要：**
> BACKGROUND: In focal segmental glomerulosclerosis (FSGS), transient receptor potential cation channel, subfamily C, member 6 (TRPC6) overactivity might cause podocyte loss and progressive kidney function decline. This exploratory study assessed the safety and efficacy of a novel once-daily oral selective TRPC6 inhibitor, BI 764198. METHODS: This multicentre phase 2, double-blind, placebo-controlled, randomised controlled trial assessed BI 764198 (20 mg, 40 mg, or 80 mg once daily) versus placebo over 12 weeks in participants aged 18-75 years with biopsy-confirmed primary FSGS (based on the absence of clinical evidence of secondary cause) or with a disease-causing TRPC6 variant. The study took place in 31 sites in ten countries, and random allocation was performed centrally in blocks in a 1:1:1:1 ratio and was stratified according to use of corticosteroids. Participants were receiving stable conservative and immunosuppressive therapy, with screening urine protein-creatinine ratio (UPCR) at 1·0 g/g or greater and estimated glomerular filtration rate at 30 mL/min per 1·73 m or greater. The primary endpoint was the proportion of participants with proteinuria response (≥25% UPCR reduction from baseline) at week 12. Other key outcomes were safety and tolerability. The study was registered with ClinicalTrials.gov on Jan 27, 2022 (NCT05213624) and is complete as of Jan 3, 2025. FINDINGS: From March 10, 2022, to Sept 3, 2024, 139 participants were screened and 67 were randomly assigned to receive placebo or BI 764198 at doses of 20 mg, 40 mg, or 80 mg (five participants were randomly assigned in error and were not treated). 62 participants received treatment, two of whom had missing baseline or post-baseline UPCR measurements and were not included in the full analysis set. Overall, 37 participants (60%) were male and 25 participants (40%) were female; the mean age was 40·7 years (SD 12·6); and the majority of the trial cohort were White (39 [63%] of 62). Proteinuria responses were observed in eight (44%) of 18, two (14%) of 14, and six (43%) of 14 participants receiving BI 764198 20 mg, 40 mg, and 80 mg, respectively (16 [35%] of 46 for all BI 764198 doses) versus one (7%) of 14 receiving placebo; corresponding odds ratios (ORs) versus placebo were OR 10·0 (95% CI 1·6-118·1), 1·5 (0·2-19·5), and 6·0 (0·9-73·6) for the three doses of BI 764198, and 4·9 (1·0-48·8) for all doses combined. BI 764198 was well tolerated with no meaningful differences in adverse event frequencies across treatment arms; treatment-emergent adverse events were reported by 44 (71%) of 62 participants, with similar frequencies of adverse events observed in the placebo group (ten [71%] of 14) and BI 764198 groups (34 [71%] of 48). INTERPRETATION: BI 764198 lowered proteinuria and was well tolerated by participants in this trial. This is the first evidence of efficacy with a podocyte-targeted therapy in FSGS. Larger randomised controlled trials over longer treatment durations, enabling meaningful subgroup analyses, are planned to evaluate the safety and efficacy of BI 764198 treatment in FSGS and other conditions affected by podocytopathy. FUNDING: Boehringer Ingelheim.

> **中文摘要：**
> 背景：在局灶性节段性肾小球硬化 (FSGS) 中，瞬时受体电位阳离子通道亚家族 C 成员 6 (TRPC6) 的过度活跃可能导致足细胞丢失和进行性肾功能下降。这项探索性研究评估了一种新型每日一次口服选择性 TRPC6 抑制剂 BI 764198 的安全性和有效性。方法：这项多中心、2 期、双盲、安慰剂对照、随机对照试验评估了 18-75 岁经活检证实的原发性 FSGS（基于缺乏继发性病因的临床证据）或携带致病性 TRPC6 变异的受试者，在 12 周内接受 BI 764198（每日一次 20 mg、40 mg 或 80 mg）与安慰剂的对比。该研究在 10 个国家的 31 个中心进行，采用中心区组随机分配，比例为 1:1:1:1，并根据糖皮质激素的使用情况进行分层。受试者接受稳定的保守治疗和免疫抑制治疗，筛选时的尿蛋白-肌酐比值 (UPCR) 为 1.0 g/g 或更高，估算肾小球滤过率 (eGFR) 为 30 mL/min/1.73 m² 或更高。主要终点是第 12 周时蛋白尿缓解（UPCR 较基线减少 ≥25%）的受试者比例。其他关键结果是安全性和耐受性。该研究于 2022 年 1 月 27 日在 ClinicalTrials.gov 注册 (NCT05213624)，并于 2025 年 1 月 3 日完成。结果：从 2022 年 3 月 10 日到 2024 年 9 月 3 日，共筛选了 139 名受试者，其中 67 名被随机分配接受安慰剂或 20 mg、40 mg 或 80 mg 剂量的 BI 764198（5 名受试者被错误分配且未接受治疗）。62 名受试者接受了治疗，其中 2 名因缺少基线或基线后 UPCR 测量值而未纳入全分析集。总体而言，37 名受试者 (60%) 为男性，25 名受试者 (40%) 为女性；平均年龄为 40.7 岁 (SD 12.6)；试验队列的大多数为白人（62 人中的 39 人 [63%]）。在接受 20 mg、40 mg 和 80 mg BI 764198 的受试者中，分别有 8 人 (44%)、2 人 (14%) 和 6 人 (43%) 观察到蛋白尿缓解（所有剂量组合计为 46 人中的 16 人 [35%]），而安慰剂组为 14 人中的 1 人 (7%)；三个剂量组与安慰剂组相比的相应比值比 (OR) 分别为 10.0 (95% CI 1.6-118.1)、1.5 (0.2-19.5) 和 6.0 (0.9-73.6)，所有剂量合并后的 OR 为 4.9 (1.0-48.8)。BI 764198 耐受性良好，各治疗组间不良事件频率无显著差异；62 名受试者中有 44 名 (71%) 报告了治疗期间出现的不良事件，安慰剂组（14 人中的 10 人 [71%]）和 BI 764198 组（48 人中的 34 人 [71%]）的发生率相似。解释：在本试验中，BI 764198 降低了蛋白尿，且受试者耐受性良好。这是首个证明足细胞靶向疗法在 FSGS 中具有疗效的证据。目前正在计划开展治疗时间更长、规模更大、能够进行有意义亚组分析的随机对照试验，以进一步评估 BI 764198 在 FSGS 及其他受足细胞病影响疾病中的安全性和有效性。资金：勃林格殷格翰。

### 第二部分 AI 大师评价

本研究是一项具有里程碑意义的 2 期临床试验，首次证明了通过抑制 TRPC6 通道实施的足细胞靶向疗法在治疗原发性 FSGS 方面的临床潜力。研究结果显示，BI 764198 能够显著提升患者的蛋白尿缓解率，且在 12 周的治疗期内展现出良好的安全性与耐受性，与安慰剂无显著差异。尽管样本量相对较小且仍处于早期探索阶段，但该研究为 FSGS 这一缺乏有效靶向疗法的罕见肾病提供了关键的药理学验证。未来更大规模的 3 期试验将是确证其长期肾脏保护获益及各亚组疗效差异的关键。

---

## 17. 前列腺癌

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41418797)
**期刊：** Lancet (London, England)
**PMID：** 41418797
**DOI：** 10.1016/S0140-6736(25)02221-4

### 第一部分 原文与翻译

**英文原标题：** Prostate cancer.

> **英文摘要：**
> Prostate cancer poses a substantial clinical challenge and accounts for a large proportion of cancer-related deaths worldwide. The therapeutic landscape has undergone a large transformation in the past 5 years, resulting in improved patient outcomes. In this Seminar, we review the pathology, diagnostic strategies, and treatments for prostate cancer. Active surveillance is the preferred treatment option for patients with indolent prostate cancer. For those requiring treatment, local therapies provide effective cancer control. Systemic treatment is essential for advanced and metastatic cases, and a wide range of therapies are now available, including androgen deprivation therapy, chemotherapy, and emerging targeted agents such as lutetium-177-labelled prostate-specific membrane antigen radioligand therapy and PARP inhibitors. Considering toxicity profiles alongside patient preferences is important to facilitating shared decision making. Further research is needed to establish the most effective sequence and combination of treatments for metastatic prostate cancer.

> **中文摘要：**
> 前列腺癌构成了重大的临床挑战，并在全球范围内占癌症相关死亡的很大比例。在过去的5年中，治疗领域经历了巨大的变革，从而改善了患者的预后。在本专题研讨中，我们回顾了前列腺癌的病理学、诊断策略和治疗方法。对于惰性前列腺癌患者，主动监测是首选的治疗方案。对于需要治疗的患者，局部治疗可提供有效的癌症控制。全身治疗对晚期和转移性病例至关重要，目前已有多种治疗手段，包括雄激素剥夺治疗、化疗，以及新兴的靶向药物，如镥-177标记的前列腺特异性膜抗原放射性配体疗法和PARP抑制剂。综合考虑毒性特征及患者偏好对于促进共同决策至关重要。需要进一步的研究来确定转移性前列腺癌最有效的治疗顺序和组合。

### 第二部分 AI 大师评价

该综述全面系统地梳理了前列腺癌的病理、诊断及最新治疗进展，重点突出了过去五年内治疗格局的剧烈转型。文章强调了分层管理的重要性，从惰性疾病的主动监测到晚期转移阶段的放射性配体疗法（RLT）及PARP抑制剂等前沿手段均有详尽论述。该文献为临床医生提供了极具价值的决策指南，并指明了探索转移性前列腺癌最优化治疗序列与组合是未来的核心研究方向。

---

速递结束，祝您工作愉快！